文献速递免疫规划慢病防控与筛查

在日本真实世界环境中评估减毒活疫苗Oka株带状疱疹疫苗后带状疱疹及带状疱疹后神经痛发病率的回顾性队列研究

A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
PubMed 文献 · Vaccine · 2024-01-03

该回顾性队列研究纳入日本一家大型医院及附属诊所中≥50岁、接种单剂VVL(BIKEN)的1175名成人,利用发药数据库和电子病历识别带状疱疹及带状疱疹后神经痛病例。中位随访3.36年期间,带状疱疹发病率为7.67/1000人年,带状疱疹后神经痛发病率为0.82/1000人年;疫苗对带状疱疹的有效性估计为27.8%(95%CI -29.8至63.9%),对带状疱疹后神经痛为73.8%(95%CI 38.6至100%)。作者认为VVL(BIKEN)预防带状疱疹效果有限,但预防带状疱疹后神经痛效果相对较好,可能作为可负担的替代选择。

要点

  • ≥50岁成人接种单剂VVL(BIKEN)后带状疱疹发病率为7.67/1000人年。
  • 带状疱疹后神经痛发病率为0.82/1000人年,疫苗有效性估计为73.8%。
  • 疫苗对带状疱疹有效性估计为27.8%,95%CI跨0,未达统计学显著。

核心结论

  • VVL(BIKEN)预防带状疱疹效果有限,但预防带状疱疹后神经痛效果相对较好,可能作为可负担的替代选择。

研究设计与样本

  • 回顾性队列研究,纳入日本一家大型医院及附属诊所中≥50岁、接种单剂VVL(BIKEN)的1175名成人。
  • 使用发药数据库和电子病历识别疫苗接种者及带状疱疹、带状疱疹后神经痛病例,并设定随访结束日期和终止原因以避免低估发病率。
  • 按年龄、性别、免疫抑制状况及免疫抑制剂治疗使用进行分层分析,并利用日本未接种人群已发表的发病率估计疫苗有效性。

主要发现

  • 中位随访3.36年期间,27名参与者诊断为带状疱疹(男性15名[2.8%],女性12名[1.9%])。
  • VVL(BIKEN)接种者带状疱疹发病率为7.67/1000人年,带状疱疹后神经痛发病率为0.82/1000人年。
  • 疫苗对带状疱疹的有效性估计为27.8%(95%CI -29.8至63.9%),对带状疱疹后神经痛为73.8%(95%CI 38.6至100%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Japan, freeze-dried live attenuated Oka-strain varicella-zoster virus vaccine, VVL (BIKEN), is available for adults aged ≥50 years to prevent herpes zoster (HZ). Although an increase in the antibody titer and cellular immune response has been demonstrated following vaccination with VVL (BIKEN), to date, no clinical studies have shown that the vaccine decreases the incidence of HZ and postherpetic neuralgia (PHN). This study investigated the incidence of HZ and PHN among adults aged ≥50 years who received a single dose of VVL (BIKEN) to prevent HZ. METHODS: This retrospective cohort study investigated the incidence of HZ and PHN among adults aged ≥50 years who received a single dose of VVL (BIKEN) at a large hospital and affiliated clinics in Japan. A dispensing database and electronic medical records were used to identify vaccine recipients and cases of HZ and PHN. The end date of the follow-up period and the reason to end the follow-up were defined to avoid underestimating the incidence. The analysis was stratified according to age, sex, immunocompromising conditions, and use of immunosuppressant therapy. Vaccine effectiveness was estimated using published estimates of the incidence of HZ and PHN in the unvaccinated population in Japan. RESULTS: A total of 1175 patients were enrolled in the study. During a median follow-up period of 3.36 years, HZ was diagnosed in 27 participants (15 men [2.8%] and 12 women [1.9%]). The incidence of HZ among VVL (BIKEN) recipients was 7.67/1000 person-years. The incidence of PHN was 0.82/1000 person-years. The vaccine effectiveness was estimated as 27.8% [95% confidence interval (CI), -29.8 to 63.9%] and 73.8% [95% CI, 38.6-100%] against HZ and PHN, respectively. CONCLUSIONS: The VVL (BIKEN) had limited effectiveness at preventing HZ, but relatively good effectiveness at preventing PHN. VVL (BIKEN) might have a role as an affordable alternative.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yaegashi M, Matsui H, Yoshida A, et al. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan. Vaccine. 2024. PMID: 38172019. doi:10.1016/j.vaccine.2023.12.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。